Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators: Discovery of 2-Chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1 H -imidazol-4-ylethynyl]pyridine (Basimglurant, RO4917523), a Promising Novel Medicine for Psychiatric Diseases
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Negative allosteric modulators (NAMs) of metabotropic glutamate receptor 5 (mGlu5) have potential for the treatment of psychiatric diseases including depression, fragile X syndrome (FXS), anxiety, obsessive-compulsive disorders, and levodopa induced dyskinesia in Parkinson's disease. Herein we report the optimization of a weakly active screening hit 1 to the potent and selective compounds chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, 2) and 2-chloro-4-((2,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1H-imidazol-4-yl)ethynyl)pyridine (CTEP, 3). Compound 2 is active in a broad range of anxiety tests reaching the same efficacy but at a 10- to 100-fold lower dose compared to diazepam and is characterized by favorable DMPK properties in rat and monkey as well as an excellent preclinical safety profile and is currently in phase II clinical studies for the treatment of depression and fragile X syndrome. Analogue 3 is the first reported mGlu5 NAM with a long half-life in rodents and is therefore an ideal tool compound for chronic studies in mice and rats.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Mosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104
Obach, R. S. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14938-0 · Cited by 1,232
Pharmacological agents acting at subtypes of metabotropic glutamate receptors
Schoepp, D. D., Jane, D. E., & Monn, J. A. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00092-1 · Cited by 1,060
Towards a glutamate hypothesis of depression
Sanacora, G., Treccani, G., & Popoli, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.036 · Cited by 1,036
Correction of Fragile X Syndrome in Mice
Dölen, G., Osterweil, E., Rao, B. S. S., Smith, G. B., Auerbach, B. D., Chattarji, S., & Bear, M. F. (2007) · Neuron · doi:10.1016/j.neuron.2007.12.001 · Cited by 979
Evans, D. A., Katz, J. L., & West, T. R. (1998) · Tetrahedron Letters · doi:10.1016/s0040-4039(98)00502-4 · Cited by 859
Metabotropic glutamate receptors in brain function and pathology
Schoepp, D. D., & Conn, P. J. (1993) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(93)90107-u · Cited by 791 · cited 1×
“a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives with affinity for GABAA α5 binding sites for”
BackgroundGasparini, F., Lingenhöhl, K., Stoehr, N., Flor, P. J., Heinrich, M., Vranesic, I., Biollaz, M., Allgeier, H., Heckendorn, R., Urwyler, S., et al. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00082-9 · Cited by 725
Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice
Michalon, A., Sidorov, M., Ballard, T. M., Ozmen, L., Spooren, W., Wettstein, J. G., Jaeschke, G., Bear, M. F., & Lindemann, L. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.009 · Cited by 489
Self-citationThe role of the amygdala in fear-potentiated startle: implications for animal models of anxiety
Davis, M. (1992) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(92)90014-w · Cited by 427
Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain
Doré, A. S., Okrasa, K., Patel, J. C., Serrano-Vega, M., Bennett, K., Cooke, R. M., Errey, J. C., Jazayeri, A., Khan, S., Tehan, B., et al. (2014) · Nature · doi:10.1038/nature13396 · Cited by 410
Cosford, N. D. P., Tehrani, L., Roppe, J., Schweiger, E., Smith, N. D., Anderson, J., Bristow, L., Brodkin, J., Jiang, X., McDonald, I., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm025570j · Cited by 396
Osterweil, E. K., Krueger, D. D., Reinhold, K., & Bear, M. F. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3888-10.2010 · Cited by 384
Tatarczyńska, E., Kłodzińska, A., Chojnacka‐Wójcik, E., Pałucha, A., Gasparini, F., Kuhn, R., & Pilc, A. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703923 · Cited by 314
Porter, R. H. P., Jaeschke, G., Spooren, W., Ballard, T. M., Büttelmann, B., Kolczewski, S., Peters, J.-U., Prinssen, E., Wichmann, J., Vieira, E., et al. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.089839 · Cited by 308
Self-citationToward Fulfilling the Promise of Molecular Medicine in Fragile X Syndrome
Krueger, D. D., & Bear, M. F. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-061109-134644 · Cited by 259
Negative Ion Tandem Mass Spectrometry for the Detection of Glutathione Conjugates
Dieckhaus, C. M., Fernández-Metzler, C. L., King, R., Krolikowski, P. H., & Baillie, T. A. (2005) · Chemical Research in Toxicology · doi:10.1021/tx049741u · Cited by 220
Varney, M. A., Cosford, N. D. P., Jachec, C., Rao, S. P., Sacaan, A., Lin, F.-F., Bleicher, L., Santori, E. M., Flor, P. J., Allgeier, H., et al. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)34881-5 · Cited by 192
Ametamey, S. M., Kessler, L. J., Honer, M., Wyss, M. T., Buck, A., Hintermann, S., Auberson, Y. P., Gasparini, F., & Schubiger, P. A. (2006) · PubMed · Cited by 183
Self-citationThe Vogel conflict test: procedural aspects, γ-aminobutyric acid, glutamate and monoamines
Millan, M. J., & Brocco, M. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01275-5 · Cited by 177
PECKNOLD, J. C., McCLURE, D. J., APPELTAUER, L., WRZESINSKI, L., & ALLAN, T. (1982) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198204000-00010 · Cited by 165
Metabotropic Glutamate 5 Receptor Antagonism Is Associated with Antidepressant-Like Effects in Mice
Li, X., Need, A. B., Baez, M., & Witkin, J. M. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.103143 · Cited by 163
Busse, C. S., Brodkin, J., Tattersall, D., Anderson, J. J., Warren, N., Tehrani, L., Bristow, L. J., Varney, M. A., & Cosford, N. D. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300540 · Cited by 159
Lan, J., Chen, L., Yu, X., You, J., & Xie, R. (2004) · Chemical Communications · doi:10.1039/b307734a · Cited by 147
Spooren, W. P. J. M., Schoeffter, P., Gasparini, F., Kuhn, R., & Gentsch, C. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01562-x · Cited by 140
Self-citationLindemann, L., Jaeschke, G., Michalon, A., Vieira, E., Honer, M., Spooren, W., Porter, R., Hartung, T., Kolczewski, S., Büttelmann, B., et al. (2011) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.185660 · Cited by 118
Self-citationBallard, T. M., Woolley, M. L., Prinssen, E. P. M., Huwyler, J., Porter, R., & Spooren, W. P. J. M. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2211-9 · Cited by 114
Self-citationMetabotropic glutamate receptor 5 as drug target for Fragile X syndrome
Scharf, S. H., Jaeschke, G., Wettstein, J. G., & Lindemann, L. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.11.004 · Cited by 106
Self-citationChapter III Metabotropic glutamate receptors — immunocytochemical and in situ hybridization analyses
Shigemoto, R., & Mizuno, N. (2000) · Handbook of chemical neuroanatomy · doi:10.1016/s0924-8196(00)80044-5 · Cited by 95
Novel glutamatergic agents for major depressive disorder and bipolar disorder
Machado-Vieira, R., Ibrahim, L., Henter, I. D., & Zarate, C. A. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.09.010 · Cited by 92
Hughes, Z. A., Neal, S. J., Smith, D. L., Rizzo, S. J. S., Pulicicchio, C. M., Lotarski, S. M., Lu, S.-P., Dwyer, J. M., Brennan, J. A., Olsen, M. A., et al. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.04.007 · Cited by 90 · cited 1×
“a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives with affinity for GABAA α5 binding sites for”
BackgroundmGlu5 receptor antagonists: A novel class of anxiolytics?
Spooren, W., & Gasparini, F. (2004) · Drug News & Perspectives · doi:10.1358/dnp.2004.17.4.829052 · Cited by 85
Self-citationMalherbe, P., Kratochwil, N. A., Mühlemann, A., Zenner, M., Fischer, C., Ståhl, M., Gerber, P. R., Jaeschke, G., & Porter, R. H. P. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03886.x · Cited by 71
Self-citationmGlu5negative allosteric modulators: a patent review (2010 – 2012)
Emmitte, K. A. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.760544 · Cited by 63
Wierońska, J. M., Szewczyk, B., Brański, P., Pałucha-Poniewiera, A., & Pilc, A. (2002) · Amino Acids · doi:10.1007/s00726-001-0131-5 · Cited by 59
mGlu5 receptor antagonists and their therapeutic potential
Jaeschke, G., Wettstein, J. G., Nordquist, R. E., & Spooren, W. (2008) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.18.2.123 · Cited by 59
Self-citationVranesic, I., Ofner, S., Flor, P. J., Bilbe, G., Bouhelal, R., Enz, A., Desrayaud, S., McAllister, K., Kuhn, R., & Gasparini, F. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.09.033 · Cited by 59
Zhang, L., Balan, G., Barreiro, G., Boscoe, B. P., Chenard, L. K., Cianfrogna, J. A., Claffey, M. M., Chen, L. M., Coffman, K. J., Drozda, S. E., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401622k · Cited by 53
The embryonic stem cell test for the early selection of pharmaceutical compounds
Whitlow, S., Bürgin, H., & Clemann, N. (2007) · ALTEX · doi:10.14573/altex.2007.1.3 · Cited by 49
Self-citationWager, T. T., Kormos, B. L., Brady, J. T., Will, Y., Aleo, M. D., Stedman, D. B., Kuhn, M., & Chandrasekaran, R. Y. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401485p · Cited by 42
Quiroz, J. A., Tamburri, P. A., Deptula, D., Banken, L., Beyer, U., da Fontoura, P. P., & Santarelli, L. (2014) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(14)70748-5 · Cited by 17
Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists
Martin, R. E., Mohr, P., Maerki, H. P., Guba, W., Kuratli, C., Gavelle, O., Binggeli, A., Bendels, S., Alvarez‐Sánchez, R., Alker, A., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.09.024 · Cited by 16
Self-citationKirchner, S., & Zeller, A. (2010) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2010.03.018 · Cited by 13
Muster, W. (2003) · Mutagenesis · doi:10.1093/mutage/geg006 · Cited by 9
Metabotropic glutamate receptors
Knöpfel, T., Madge, D., & Nicoletti, F. (1996) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.6.10.1061 · Cited by 5
Research works printed but not linked: 4
- Rodriguez A. L., 2007, Curr. Opin. Drug Discovery Dev., 10, 715
- Lindsley C. W., 2009, Curr. Opin. Drug Discovery Dev., 12, 446
- Lindemann L., 2014, Curr. Neuropharmacol., 12, 35
- Ametamey S. M., 2006, J. Nucl. Med., 47, 698
Cited by
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Structure, function and drug discovery of GPCR signaling
Cheng, L., Xia, F., Li, Z., Shen, C., Yang, Z., Hou, H., Sun, S., Feng, Y., Yong, X., Tian, X., et al. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00156-w · Cited by 152
FragXis Study Group, Youssef, E. A., Berry-Kravis, E., Czech, C., Hagerman, R. J., Hessl, D., Wong, C. Y., Rabbia, M., Deptula, D., John, A., et al. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.177 · Cited by 133
“The early short-term clinical trials with mGluR5 NAMs, including basimglurant, assessing the effects in individuals with FXS, were supportive of further exploration in larger, well-controlled trials.”
BackgroundInfluentialSelf-citationQuiroz, J. A., Tamburri, P., Deptula, D., Banken, L., Beyer, U., Rabbia, M., Parkar, N., Fontoura, P., & Santarelli, L. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0838 · Cited by 133
Fu, T., Zheng, G., Tu, G., Yang, F., Chen, Y., Yao, X., Li, X., Xue, W., & Zhu, F. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00059 · Cited by 115
Metadata
- Authors
- Jaeschke, G., Kolczewski, S., Spooren, W., Vieira, E., Bitter-Stoll, N., Boissin, P., Borroni, E., Büttelmann, B., Ceccarelli, S., Clemann, N., David, B., Funk, C., Guba, W., Harrison, A., Hartung, T., Honer, M., Huwyler, J., Kuratli, M., Niederhauser, U., Pähler, A., Peters, J.-U., Petersen, A., Prinssen, E., Ricci, A., Rueher, D., Rueher, M., Schneider, M., Spurr, P., Stoll, T., Tännler, D., Wichmann, J., Porter, R. H., Wettstein, J. G., & Lindemann, L.
- Affiliations
- F. Hoffmann-La Roche AG (CH)
- University of Basel (CH)
- Corresponding author
- Jaeschke, Georg
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-02-02
- Volume
- 58
- Issue
- 3
- Pages
- 1358-1371
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2011170609
- Cited by
- 66
- References
- 45
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 3 · 2023: 8 · 2021: 4 · 2020: 2 · 2019: 8 · 2018: 6 · 2017: 12 · 2016: 7 · 2015: 10
- FWCI
- 5.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- metabotropic glutamate receptor 5, negative allosteric modulators, CTEP, antidepressant drug discovery, fragile X syndrome, anxiety, depression, levodopa-induced dyskinesia, drug metabolism and pharmacokinetics, preclinical safety, structure-activity optimization
- MeSH terms
- Allosteric Regulation, Animals, Depression, Dose-Response Relationship, Drug, Fragile X Syndrome, Humans, Imidazoles, Macaca mulatta, Male, Mice, Inbred Strains, Pyridines, Structure-Activity Relationship, Molecular Structure, Rats, Sprague-Dawley, Rats, Wistar, Mice, Rats, Drug Discovery, Receptor, Metabotropic Glutamate 5
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.